Stockscreener 앱 받기
1.6607
1.73%
-0.0293
시간 외 거래:
1.66
-0.0007
-0.04%
Beyondspring Inc 주식(BYSI)의 최신 뉴스
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - PR Newswire UK
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - PR Newswire UK
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire
BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online
Biotech Stocks Facing FDA Decision In November - RTTNews
BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx
G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
Chemotherapy Induced Neutropenia Market Size is Set for Rapid - openPR
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance
BeyondSpring Inc. Reports Mid-Year Financials - TipRanks
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat
BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com
BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com
BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products - Scrip
BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online
Chemotherapy Induced Neutropenia Market Forecasted to Surge - openPR
SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - StockTitan
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - 新浪香港
0.50%
1.47%
자본화:
|
볼륨(24시간):